Suoquan pill for the treatment of diabetic nephropathy: A protocol for systematic review and meta-analysis.
Suoquan pill for the treatment of diabetic nephropathy: A protocol for systematic review and meta-analysis.
复制标题
锁泉丸治疗糖尿病肾病
DOI：
10.1097/md.0000000000025613
复制
发表时间：
2021-04-30
期刊：
影响因子：
1.6
通讯作者：
Yin D
中科院分区：
文献类型：
--
作者：
Cai P;Wu Z;Huang W;Niu Q;Zhu Y;Yin D
摘要背景：糖尿病肾病是发达国家糖尿病最常见的并发症之一，也是导致肾功能衰竭的主要原因。临床上，糖尿病肾病通常通过控制血糖和血压来治疗。据报道，血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂的应用只能针对疾病发展的一定阶段。然而，锁泉丸在中医中的应用却产生了明显的临床疗效和较小的副作用。它被用来治疗糖尿病肾病和其他疾病，但还没有对SQP治疗糖尿病肾病的系统评价。本文就SQP治疗糖尿病肾病的有效性和安全性作一综述。方法：数据库将随机对照试验(RCT)的注册日期设置为2021年3月25日。检索Cochrane图书馆、Embase、PubMed、Science Net、中国国家知识基础设施、中国生物医学文献数据库等8个中英文电子数据库。中文科学期刊数据库和万方数据库进行分析。主要观察临床疗效、尿白蛋白排泄率、症状积分和生活质量。最后，使用STATA 15进行Meta分析。结果：本研究将从临床疗效、尿白蛋白排泄率、生活质量、症状积分等方面为SQP治疗糖尿病肾病提供最新证据。结论：本研究结果将为评价SQP治疗糖尿病肾病的疗效提供依据。OSF注册号：10.17605/OSF.IO/KZ9RA
Abstract Background: Diabetic nephropathy (DN) is one of the most common complications of diabetes and the main cause of kidney failure in developed countries. Clinically, DN is usually treated by controlling blood sugar and blood pressure. According to reports, the application of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist can only target a certain stage of disease development. However, the application of Suoquan Pill (SQP) in traditional Chinese medicine has produced obvious clinical effects and minor side effects. It is used to treat DN and other diseases, but there is no systematic review of SQP in the treatment of diabetic nephropathy. This article reviews the effectiveness and safety of SQP in the treatment of DN. Methods: The database sets the registration date for randomized controlled trials (RCT) to March 25, 2021. By searching the following eight Chinese and English electronic databases: Cochrane Library, Embase, PubMed, Science Net, China National Knowledge Infrastructure, China Biomedical Literature Database. Chinese scientific journal database and Wanfang database for analysis. The main results are clinical efficacy, urinary albumin excretion rate, symptom score and quality of life. Finally, Stata 15 was used for meta-analysis. Results: This study will provide the latest evidence for SQP in the treatment of DN in the following aspects: clinical efficacy, urinary albumin excretion rate, quality of life, symptom score. Conclusion: The results of this study will provide evidence for evaluating the effectiveness of SQP in the treatment of DN. OSF registration number: 10.17605/OSF.IO/KZ9RA